The Medical Advisor

Summary  The video script discusses the importance of maintaining heart health and how to lower blood pressure. It covers topics such as the role of the heart, blood, cholesterol, and blood vessels in heart health. It also addresses the myths surrounding cholesterol, salt, and blood thinners. The script emphasizes the significance of exercise, nutrition, stress management, and proper breathing techniques in maintaining a healthy heart. Highlights 🩺 The script challenges the myth that cholesterol causes heart disease, citing multiple sources and experts. 💊 It highlights the potential dangers and side effects of cholesterol-lowering medication, such as memory loss and increased risk of dementia. 🧂 The script dispels the misconception that salt is universally harmful and discusses the importance of using natural, minimally processed salts. 🏋️ The script emphasizes the role of exercise in strengthening the heart and improving overall heart health. 🌬️ It explains the significa...

Is high blood pressure a silent killer — or a misunderstood metric driving overtreatment? The truth lies in between. High blood pressure has long been framed as a universal villain: a condition that must be aggressively lowered, often for life, to prevent heart attacks, strokes, and early death. Yet critics argue that hypertension has become overdiagnosed, overtreated, and detached from its biological context (1). So which is it — lifesaving intervention or medical overreach? The answer is more complex than either side admits. This article critically examines the modern blood pressure paradigm: where it is evidence-based, where it falls short, and how patients can navigate care without falling into either blind compliance or blanket rejection. How Hypertension Became a Medical Absolute Blood pressure is easy to measure, inexpensive to monitor, and strongly correlated with cardiovascular risk at a population level. That combination made it an ideal screening metric — and eventually, a t...

Introduction Linoleic acid (LA) is the most abundant omega‑6 polyunsaturated fatty acid (PUFA) in modern diets. It is found primarily in seed and vegetable oils such as soybean, corn, sunflower, safflower, and canola oil, as well as in nuts, seeds, and some animal foods. Because industrial food production dramatically increased omega‑6 intake over the past century, linoleic acid has become a focal point of controversy. Some commentators claim it drives inflammation, obesity, metabolic disease, mitochondrial damage, cancer, and cardiovascular disease. This article reviews the best available human evidence, separates mechanistic speculation from clinical reality, and explains how linoleic acid actually fits into a healthy diet. What Is Linoleic Acid? Linoleic acid is an essential fatty acid , meaning the human body cannot synthesize it. It is required for: Cell membrane structure and fluidity Skin barrier function Normal immune signaling Production of longer‑chain fatty acids Deficiency ...

Introduction Cancer metabolism has emerged as a promising area of research, with growing interest in therapies that target cellular energy pathways, inflammation, and metabolic vulnerabilities. Beyond conventional surgery, chemotherapy, radiation, and immunotherapy, a range of metabolic interventions—dietary approaches, repurposed drugs, supplements, and lifestyle modifications—are being investigated for their potential to support cancer control or enhance treatment response. While mainstream oncology guidelines (ASCO, NCCN, ESMO) prioritize interventions supported by high-quality randomized controlled trials (RCTs) and meta-analyses, many metabolic interventions rely on mechanistic plausibility, preclinical studies, observational data, or small case series. This article evaluates these emerging strategies, emphasizing evidence strength and translational potential rather than definitive therapeutic claims. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figure ...

Introduction Repurposing existing drugs for oncology offers a promising pathway to identify affordable, globally accessible therapies for advanced cancer. These agents may modulate metabolism, inflammation, or cellular stress pathways relevant to tumor growth. However, mainstream oncology guidelines (ASCO, NCCN, ESMO) recommend interventions only when supported by robust clinical evidence , typically from randomized controlled trials (RCTs) or well-designed prospective studies. Mechanistic plausibility, in vitro studies, or anecdotal cases alone do not constitute sufficient evidence to guide treatment. This article reviews 19 repurposed drugs highlighted in the OneDayMD AI ranking , situating each within an evidence-aware framework , and clarifies the distinction between AI-generated prioritization and clinical validation. Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figure was created with Biorender.com. Source:  Nature 2024 Evidence Tier Framework To...

Abstract The antiparasitic agents fenbendazole, mebendazole and ivermectin have recently emerged as promising candidates for adjunctive cancer therapy due to their multifaceted anticancer mechanisms and favorable safety profiles. Fenbendazole and mebendazole, benzimidazole derivatives, exert antitumor effects primarily through microtubule disruption and metabolic interference, inducing cell cycle arrest and apoptosis. Ivermectin, a macrocyclic lactone, complements these actions by inhibiting oncogenic signaling pathways such as STAT3, Wnt/β-catenin, and AKT/mTOR, while modulating immune responses.  Recently, ivermectin has been investigated not only in dual combinations with benzimidazoles but also as part of a triple‑agent strategy involving fenbendazole and mebendazole to potentially enhance anticancer effects. Systematic reviews of publicly reported case data suggest temporal associations between this triple combination and tumor regression across diverse malignancies, although...